Sinocelltech Group Limited (SHA: 688520)

Market Cap	17.28B
Revenue (ttm)	2.45B
Net Income (ttm)	-26.10M
Shares Out	445.34M
EPS (ttm)	-0.06
PE Ratio	n/a
Forward PE	61.59
Dividend	n/a
Ex-Dividend Date	n/a

Volume	2,184,033
Open	38.42
Previous Close	38.38
Day's Range	38.02 - 39.45
52-Week Range	31.07 - 56.50
Beta	0.61
Analysts	n/a
Price Target	n/a
Earnings Date	Apr 11, 2025

About Sinocelltech Group

Sinocelltech Group Limited, a biotech company, engages in the research and development, and industrialization of recombinant proteins, monoclonal antibodies, and vaccines in China. The company offers AnpingxiA (repertuzumab injection), an anti-tumor product; Anjiayin for the treatment of the rare disease hemophilia A; coronavirus 2-valent, a trimer protein vaccine; and mutant strain recombinant protein vaccines SCTV01C and SCTV01E. Its pipeline products include SCT630 used for the treatment of autoimmune diseases; SCT510 for the treatment of so...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2007
• Employees: 2,313
• Stock Exchange: Shanghai Stock Exchange
• Ticker Symbol: 688520

Financial Performance

In 2023, Sinocelltech Group's revenue was 1.89 billion, an increase of 84.46% compared to the previous year's 1.02 billion. Losses were -396.02 million, -23.70% less than in 2022.